U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519811) titled 'LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and O... Read More
U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520279) titled 'Xpert(R) Tropical Fever Test on GeneXpert(R) Edge X System' on March 18. Brief Summary: T... Read More
U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520669) titled 'Does Capsuloplasty Reduce External Rotation After Coracoid Impingement?' on April 03. Bri... Read More
U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519746) titled 'Satisfaction and Quality of Life Among Prosthetic Users in Gaza Governorate ,' on Aug. 21,... Read More
Singapore, April 10 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 10 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 10 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, April 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, April 10 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, April 10 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More